Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

2014
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-31T21:40:17
publisher: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir
label: RDF description of Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir - http://research.umh.es/vivo/pub/articulo/151393

Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir
type: Document
related by: Autor:35232-Artículo:151393
date time value: 151393 pubdate
type: Article
ARG_2000028: 151393 vcard
type: Information Content Entity
type: 2014
related by: AutorExt:245105_2014-Artículo:151393
type: Entity
has publication venue: ANTIVIRAL THERAPY
type: Thing
related by: AutorExt:245100_2014-Artículo:151393
related by: AutorExt:245102_2014-Artículo:151393
type: Academic Article
page end: 20
related by: AutorExt:245101_2014-Artículo:151393
most specific type: 2014
type: Generically Dependent Continuant
related by: AutorExt:245103_2014-Artículo:151393
type: Anualidad
related by: AutorExt:245104_2014-Artículo:151393
page start: 1
type: Continuant
most specific type: Academic Article

Autor:35232-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

AutorExt:245105_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

ANTIVIRAL THERAPY
type: Journal
type: Continuant
type: Thing
type: Periodical
publication venue for: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir
type: Information Content Entity
type: Collection
type: Generically Dependent Continuant
type: Entity

AutorExt:245100_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

AutorExt:245102_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

AutorExt:245101_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

AutorExt:245103_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

AutorExt:245104_2014-Artículo:151393
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir